Skip to content

Share Buybacks at other companies

Alkermes logo
AlkermesALKS
$27.7M

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%

Returns & leverage

See full
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's share buybacks?
Indivior Pharmaceuticals, Inc. (INDV) reported share buybacks of $126M in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's share buybacks changed year-over-year?
Indivior Pharmaceuticals, Inc. 's share buybacks increased by 1045.5% year-over-year, from $11M to $126M.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's share buybacks?
Over 2 years (2022 to 2024), Indivior Pharmaceuticals, Inc. 's share buybacks has grown at a 38.6% compound annual growth rate (CAGR), from $90M to $173M.
What does share buybacks mean?
Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.